LOUISVILLE, Ky. -- Chi-Chi's, Inc., a Mexican restaurant chain headquartered in Louisville, Ky., today announced that the company had decided to voluntarily extend the closure of its Chi-Chi's restaurant at the Beaver Valley Mall to a minimum of 60 days.
"From the point that we first became aware of this outbreak, our primary concern has been to protect the health, safety and well being of our employees and the local community," said Bill Zavertnik, chief operating officer of Chi-Chi's, Inc. "This decision reflects the high standard of caution that we have taken in responding to this outbreak and the overriding importance we place on food safety."
According to the company's medical advisor, the maximum incubation period for hepatitis A is 50 days. All of Chi-Chi's employees have been tested for the infection.
"We have voluntarily decided to extend the closure of this location until at least 60 days from our initial closure on Nov. 2, 2003. We will not reopen until we have total confidence that the location is safe, every employee has been definitively cleared of the infection and we have consulted with all the participating public health authorities," said Zavertnik. "I would like to stress that none of our other restaurants are involved, where we continue to offer our guests a fun and safe environment to enjoy great Mexican food."
The chain operates 100 company-owned restaurants in the Midwest and eastern United States.
Source: Chi-Chi's, Inc.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.